SpyGlass Pharma, Inc. Common Stock (SGP) financial statements and ratios from SEC XBRL: revenue $3.11M (TTM), net margin -1283.6%, revenue growth 1162.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $3.11M |
| Net Margin | -1283.6% |
| Revenue Growth (YoY) | 1162.7% |
| EPS Growth (YoY) | -82.6% |
| FCF Growth (YoY) | 70.0% |
| Price / Book | 3.50 |
| FCF Yield | -2.6% |
| Altman Z-Score | 1.07 (distress) |
| Sector P/E (Healthcare) | 21.6 |
SGP overview · SGP earnings · SGP KPIs · SGP investor relations · SGP ownership · SGP peers · SGP filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.